Medications

Q&A: Experts discuss pros, cons of new Alzheimer's drug

Patient care teams are preparing to offer lecanemab, a new Alzheimer's disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.

Neuroscience

ClearTau: A new tool for studying neurodegenerative diseases

EPFL scientists have developed ClearTau, an innovative method and platform for reconstructing aggregates of the protein Tau found in Alzheimer's disease and other neurodegenerative diseases. The breakthrough may speed up ...

Health

Intranasal insulin may have pro-cognitive benefits

Intranasal insulin (INI) seems to have a beneficial effect on global cognition among patients with Alzheimer's disease (AD)/mild cognitive impairment (MCI), according to a review published online June 28 in PLOS ONE.

page 33 from 40